Fisher R I, Hubbard S M, DeVita V T, Berard C W, Wesley R, Cossman J, Young R C
Blood. 1981 Jul;58(1):45-51.
Clinical and histopathologic material from 151 cases of diffuse mixed, diffuse histiocytic, and diffuse undifferentiated non-Burkitt's lymphomas have been reviewed to determine the factors that predict long-term survival. Median survival of all patients was 34 mo with 43% alive at 70 mo. Factors associated with a poor prognosis include: male sex, constitutional symptoms, advanced stage, bone marrow involvement, huge (greater than 10 cm) abdominal masses with gastrointestinal involvement, hepatic involvement, hemoglobin greater than 12 g/dl, or serum LDH greater than 250 U. The best prediction of a given patient's survival was defined by a set of four variables, which includes sex, symptoms, bone marrow status, and the presence or absence of a huge abdominal mass with gastrointestinal involvement. In contrast, classification of these patients according to the histopathologic categories of Rappaport of Strauchen did not define patient groups with significant differences in survival, nor did these categories correlate with the previously described clinical factors. Knowledge of the distribution of these prognostic factors in any clinical trial is needed before therapeutic results can be compared. In addition, such data may define subsets of patients for whom current therapy is inadequate and conversely those patients for whom current therapy yields excellent long-term survival.
回顾了151例弥漫性混合性、弥漫性组织细胞性和弥漫性未分化非伯基特淋巴瘤的临床和组织病理学资料,以确定预测长期生存的因素。所有患者的中位生存期为34个月,70个月时43%存活。与预后不良相关的因素包括:男性、全身症状、晚期、骨髓受累、伴有胃肠道受累的巨大(大于10 cm)腹部肿块、肝脏受累、血红蛋白大于12 g/dl或血清乳酸脱氢酶大于250 U。对特定患者生存的最佳预测由一组四个变量定义,包括性别、症状、骨髓状态以及是否存在伴有胃肠道受累的巨大腹部肿块。相比之下,根据斯特劳申的拉帕波特组织病理学分类对这些患者进行分类,并未明确生存存在显著差异的患者组,这些分类也与先前描述的临床因素无关。在比较治疗结果之前,需要了解任何临床试验中这些预后因素的分布情况。此外,此类数据可能会确定当前治疗不足的患者亚组,以及相反地确定当前治疗能产生极佳长期生存的患者。